Overview

CC-4047 in Treating Patients With Myelofibrosis

Status:
Completed

Trial end date:
2019-12-12

Target enrollment:

Participant gender:

Summary

RATIONALE: Biological therapies, such as CC-4047, may stimulate the immune system in different ways and stop cancer cells from growing. CC-4047 may also stop the growth of cancer cells by blocking blood flow to the cancer. PURPOSE: This trial is studying the side effects and best dose of CC-4047 and to see how well it works in treating patients with myelofibrosis.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Mayo Clinic

Collaborator:

National Cancer Institute (NCI)

Treatments:

Pomalidomide
Thalidomide